IRVINE, Calif., March 22, 2006 (PRIMEZONE) -- "Stem cell research clearly appears to be one of the most important scientific discoveries of the past decade, inspiring hope in a wide variety of medical applications," said SmallCap Sentinel analyst D.R. Clark. "Additionally, recent successes and research findings regarding adult stem cells have provided what may well be an ethical compromise to the more controversial use of embryonic stem cells."
"Recent reports also indicate that some adult stem cell research is further along in its commercial development than many embryonic studies," said Clark. "Along these lines, Samaritan Pharmaceuticals, Inc. (AMEX:LIV) announced that its Alzheimer's adult stem cell drug SP-sc04, which induces dormant brain neuronal stem cells to differentiate rapidly into adult neuron cells, is progressing through preclinical studies with promising results," said Clark.
The informational report, "Looking at the Political Impact on Stem Cell Research," addressing the aforementioned companies and others, is available at http://www.SmallCapSentinel.com and will address companies including Orthovita Inc (Nasdaq:VITA), Aastrom Biosciences Inc. (Nasdaq:ASTM), and Boston Scientific Corporation (NYSE:BSX).
Samaritan is a drug development company driven to discover, develop and commercialize new, innovative drugs for AIDS, Alzheimer's, Cancer and Heart disease. Samaritan is currently advancing eight promising compounds out of its rich pipeline of 250 possible drug candidates, all of which have the potential to create revenue-generating opportunities.
A free detailed informational report regarding Samaritan is available at the following link: http://stockupticks.com/profiles/3-15-06.html
A Research Report on Samaritan Pharmaceuticals can be downloaded at the company's website: http://www.shareholder.com/samaritan/reports.cfm
Individuals may also register to receive future reports at: http://stockupticks.com/register.html
SmallCap Sentinel and StockUpTicks.com are publications of financial courier Market Pathways, a twenty-two year old full-service financial relations firm offering information on specific public companies to interested investors. To have your company featured in StockUpTicks or SmallCap Sentinel, please use the contact information below.
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect results. SmallCapSentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy or offer to sell securities but is rather a paid advertisement provided for information purposes only and shouldn't be used as the basis for investment decisions. MP is not an investment advisor and this report is not investment advice. MP was paid $5,000 by Samaritan Pharmaceuticals for preparation of this profile and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.